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Abstract
A good prognosis can be expected for most, but not all, cases of thyroid papillary cancer. Numerous molecular studies have
demonstrated beneficial treatment and prognostic factors in various molecular markers. Whereas most previous reports
have focused on genomics and proteomics, few have focused on lipidomics. With the advent of mass spectrometry (MS), it
has become possible to identify many types of molecules, and this analytical tool has become critical in the field of omics.
Recently, imaging mass spectrometry (IMS) was developed. After a simple pretreatment process, IMS can be used to
examine tissue sections on glass slides with location information. Here, we conducted an IMS analysis of seven cases of
thyroid papillary cancer by comparison of cancerous with normal tissues, focusing on the distribution of phospholipids. We
identified that phosphatidylcholine (16:0/18:1) and (16:0/18:2) and sphingomyelin (d18:0/16:1) are significantly higher in
thyroid papillary cancer than in normal thyroid tissue as determined by tandem mass (MS/MS) analysis. These distributional
differences may be associated with the biological behavior of thyroid papillary cancer.
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Introduction
Thyroid cancer is the most common malignant tumor in the
head and neck region. The histological types of thyroid cancer
vary, and include papillary carcinoma (80% of all thyroid cancer
cases), follicular carcinoma, medullary carcinoma, and undiffer-
entiated carcinoma. Prognosis also varies depending on histolog-
ical type. Undifferentiated carcinoma has a poor prognosis, with a
10-year survival rate of 10–20% or less, whereas patients with
other histological types, such as papillary carcinoma, follicular
carcinoma, and medullary carcinoma, can expect good outcomes
with a 10-year survival rate of 90%, 90%, and 70–80%,
respectively [1]. However, even cases of papillary carcinoma can
fail to be controlled due to distant metastasis or anaplastic
transformation. It will be necessary to reliably predict anaplastic
transformation before it occurs, and to identify cases of poor
prognosis among papillary carcinomas, in order to improve the
overall prognosis of thyroid cancer.
Developments in genomics and molecular biology have shed
light on pathogenic mechanisms related to thyroid cancer [2].
Great efforts have been made to identify genes and biomolecules
that are differentially expressed in cancerous tissues, which can be
utilized as biomarkers to elucidate thyroid cancer pathogenesis
and guide appropriate and targeted molecular therapies [3,4,5].
Several candidate genes (for TSH receptors, RET/PTC, Ras,
BRAF, p53) in the development of different types of thyroid cancer
[2] have been identified thus far. In addition, some attempts have
been made to utilize proteomics as a tool of discovery for thyroid
neoplasms. Lewis and co-workers reported a difference in protein
expression between papillary thyroid carcinoma and normal
thyroid tissue using mass spectrometry (MS) [6]. However, the
mechanism of malignant transformation is not well understood,
especially at the protein level.
Lipids are associated with cell membrane structure, proliferation
[7], differentiation, metabolic regulation, inflammation [8], and
immunity. It is important to understand the relationship between
tumor and lipids in diagnosis and treatment. Lipids, especially
phospholipids (PLs), play important roles in the composition of the
cell membrane. It is generally accepted that membrane charac-
teristics are determined by the components of PL species, and the
composition of these species is strictly determined by the
components of fatty acid species [9,10]. A few reports conducted
to date have focused on lipids, especially binding fatty acids in
head and neck cancer; however, to date, no method has been
developed that enables the detection of binding fatty acids in PLs.
Imaging mass spectrometry (IMS) is a powerful, newly
developed tool that identifies the distribution of known/unknown
molecules on a tissue section [11,12,13]. Laser scanning enables
precise, two-dimensional MS on glass slides. Currently, IMS is the
only tool that allows for visualization of the binding of fatty acids
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to PLs on tissue sections, and this next-generation approach is
attracting substantial attention.
The purpose of the present study was to use IMS to elucidate
which PL-bound fatty acids were the main components of cell
membranes, and in particular, which ones were expressed at
relatively high levels in thyroid papillary cancer. This study was
the first to investigate cases of PLs in thyroid cancer using IMS
analysis, and the first to successfully identify PLs that are highly
expressed in thyroid cancer.
Results
1. IMS analysis of case 1
The regions of interest (ROI) in cancer and normal regions were
defined according to hematoxylin and eosin (HE)-staining results
of a tissue section adjacent to the section used for IMS analysis.
Figure 1A provides HE-staining results for case 1 while Figure 1B
shows magnified representative regions of cancer and normal
tissue. The cancer cells had a high cytoplasmic ratio and displayed
nuclear features characteristic of papillary thyroid cancer.
Histologic findings of thyroid papillary cancer consisted of
columnar thyroidal epithelium set in papillary projection. The
normal thyroid tissue is composed of many spherical hollow sacs
called thyroid follicles.
Figure 2 shows spectra obtained from case 1 tissue with panels A
and B derived from cancer and normal regions, respectively. Both
spectrums are average spectrums, and were obtained from ROI in
cancer and normal tissue. The number of calculated points in the
cancer and normal region was 1425 and 258, respectively. The
horizontal axis indicates the mass-to-charge ratio (m/z) and the
vertical axis indicates the relative abundance of the ion. The most
intense ion is assigned an abundance of 100, and is referred to as
the base peak. Most ions formed in a mass spectrometry have a
single charge, so that the m/z value is equivalent to the mass itself.
Table 1 shows the top 50 peak picking results for case 1
(excluding isotopic peaks) that were statistically analyzed. Cancer
and normal intensity means the average (6 standard error)
intensity that was divided by the scanning point in cancer and
normal regions. Welch t-test was performed between the mean
intensity of cancer and normal regions. The m/z values in Table 1
are listed in order of their intensity in the cancer region. The
number of the m/z values without isotopic peaks was 40, and the
number of the values with significant differences was 26. All m/z
values in Table 1 were assigned using the spectrum shown in
Figure 2A and B.
2. Visualization of molecular distribution in thyroid tissue
of case 1
Figure 3 shows the ion image that was visualized using the m/z
values shown in Table 1. The range of each ion color images was
optimized manually, so the peaks have different color ranges. In
general, malignant cellular proliferation was stimulated due to cell
growth factors, which induce an increase in cell density and
components of cancer cells such as PLs. Therefore, while the
intensity of all m/z values should be higher in cancer regions, the
intensity of some values (in particular, m/z 772.5, 782.5 and 848.5)
in cancer regions was lower.
Figure 1. HE-stained section of case 1. (A) Thyroid papillary cancer
tissue was localized on the left, and normal thyroid tissue was localized
on the right (original magnification 406). The stromal region was
excluded. The ROI was determined from the corresponding HE-staining
results. The black boxes indicate the representative region of cancer
and normal thyroid tissue. (B) Magnified representative regions of
cancer and normal tissue (original magnification 2006). The cancer cells
had a high cytoplasmic ratio and displayed nuclear features character-
istic of papillary thyroid cancer. Histologic findings of thyroid papillary
cancer consisted of columnar thyroidal epithelium set in papillary
projection. The normal thyroid tissue is composed of many spherical
hollow sacs called thyroid follicles.
doi:10.1371/journal.pone.0048873.g001
Figure 2. Averaged spectrum for case 1. (A) Spectrum of the cancer region and (B) spectrum of normal region. Each spectrum was averaged
from the ROI of cancer and normal tissue in Figure 1. Each number shown in Table 1 was assigned using these spectra.
doi:10.1371/journal.pone.0048873.g002
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3. Comparison of results in all cases
In the same manner as case 1, peak picking and statistical
analysis were performed on all cases. Table 2 shows the top 50
peak picking results and excludes isotopic peaks. The m/z values
showing no significant differences were excluded. Three m/z
values*, including m/z 798.5, 796.5, and 741.5, were found to be
common for all cases.
The common m/z values in all cases are displayed in Figure 4.
ROIs of cancer and normal tissue in all cases were described in
HE-stained results for all cases. The intensity of nearly all m/z
values was higher in the cancer region compared to the normal
thyroid region. Only the intensity distribution of m/z 741.5
differentiated them from the others.
4. Molecular identification
The three common m/z values in all cases were subjected to
tandem mass (MS/MS) analysis to identify the structures of the
biomolecules associated with the precursor ions. (Figure 5). The
Metabolite MS Search (http://www.hmdb.ca/labm/jsp/mlims/
MSDbParent.jsp) was used for referencing.
In MS/MS for PLs with cations, certain characteristic fragment
peaks are often detected. The peak at m/z 798.5 (Figure 5A) was
identified as phosphatidylcholine (PC) due to the neutral loss of
59 Da and 183 Da during MS/MS, which is indicative of PC
[14,15]. Meanwhile, the neutral loss of 256 Da corresponded to
palmitic acid. The type of cation adducted to a biomolecule is
usually either a sodium or potassium ion, when the sample is
obtained from biological tissue. A difference of 38.0 was observed
between the m/z 577.5 and 615.5, which is consistent with the
replacement of a potassium ion (molecular weight, 39.10) with a
proton (molecular weight, 1.01). According to a Metabolite MS
search, the peak at m/z 798.5 indicates [PC (16:0/18:1)+K]+. In
the same manner, we concluded that m/z 796.5 corresponded to
[PC (16:0/18:2)+K]+ (Figure 5B).
The results of m/z 741.5 showed peaks of m/z 682.4 and 558.4
(Figure 5C). The peak at m/z 682.4 corresponded to neutral loss of
trimethylamine (59 Da), and the peak at m/z 577.5 corresponded
to neutral loss of trimethylamine (59 Da) and cyclophosphate
(124 Da). The peak at m/z 184 corresponded to trimethylamine
(59 Da), cyclophosphate (124 Da) and a proton ion (1 Da). These
results indicated that m/z 741.5 contained an alkali metal adduct
phosphocholine; therefore, m/z 741.5 was a PC or sphingomyelin
(SM) species. Applying the nitrogen rule to phospholipids, the odd
nominal mass indicated SM due to the presence of an additional
nitrogen in the sphingosine of SM. We thus concluded that m/z
741.5 was a SM species. The Metabolite MS search indeed
suggested that m/z 741.5 corresponded to [SM (d18:0/16:1)+K]+.
Discussion
For more than a century, pathological examinations have been
the primary and most important tool for the diagnosis of cancerous
regions. Cancer classification itself has been established based on
the findings of classical staining methods such as HE staining, and
such methods will continue to play a leading role in cancer
diagnosis. However, the limitations of classification based on
classical staining findings should be noted. It is often the case that
patients with the same pathological diagnosis do not always have
the same prognosis. Diagnoses are often made based on
morphology. Using conventional pathological techniques, we can
only conduct morphological observations, and it is difficult to
reveal the details of components in tissue sections. In situ
hybridization and/or immunohistochemistry analyses enable the
analysis of the distribution of known molecules; however, it has
remained impossible to examine the distribution of unknown
molecules. For a detailed and accurate diagnosis, it is necessary to
obtain information regarding components such as specific proteins
and lipids in a sample.
As an important technique in the proteome generation post-
genome era, MS has become widely used in numerous medical
fields for the diagnosis and treatment of various diseases, including
Table 1. Peak picking and statistical analysis of mass spectra
in case 1.
m/z value Cancer Normal P value
798.5 37.161.2 28.562.6 3.3E-03
824.5 26.760.8 26.662.4 9.7E-01
796.5 25.160.9 17.761.7 1.0E-04
618.1 20.461.0 5.160.6 4.3E-33
529.6 17.061.0 3.760.4 2.3E-29
580.2 16.261.1 2.060.3 7.1E-34
822.4 15.960.5 13.461.3 6.7E-02
504.2 15.661.1 6.760.8 5.7E-11
741.5 14.060.5 11.161.0 8.5E-03
664.2 9.560.9 0.360.1 7.9E-23
616.3 9.061.0 4.161.7 1.6E-02
826.5 8.760.3 8.960.9 8.4E-01
820.5 7.860.3 9.061.1 2.6E-01
584.1 7.460.7 1.460.2 3.9E-17
622.0 6.760.6 1.660.3 9.6E-14
760.6 6.560.4 7.761.0 2.4E-01
758.5 6.360.4 7.660.9 1.8E-01
527.2 6.260.6 3.860.5 3.1E-03
782.5 5.560.2 12.761.3 7.1E-08
542.3 5.560.5 0.260.0 6.5E-26
772.5 5.460.2 12.461.9 5.2E-04
615.0 5.460.2 1.360.1 1.8E-51
848.5 5.060.2 8.661.0 6.0E-04
546.2 4.860.4 0.460.1 2.2E-22
786.5 4.660.3 7.260.9 3.6E-03
704.1 4.060.3 0.560.1 1.8E-25
599.1 3.960.1 3.960.3 9.8E-01
659.8 3.760.3 1.360.2 3.2E-09
666.2 2.760.3 0.160.0 1.1E-18
508.3 2.660.3 0.260.0 3.3E-16
606.0 2.560.3 1.760.3 4.2E-02
808.1 2.560.2 2.160.7 6.0E-01
602.2 2.360.2 1.660.3 4.6E-02
565.2 2.060.2 2.160.3 8.8E-01
643.9 1.360.2 1.260.2 6.2E-01
734.5 0.760.1 3.260.7 1.8E-04
561.0 0.760.1 0.060.0 2.7E-15
620.2 0.360.1 0.160.0 2.2E-03
590.1 0.260.0 0.260.0 6.2E-01
589.1 0.160.0 0.060.0 2.8E-04
doi:10.1371/journal.pone.0048873.t001
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cancer. Numerous novel biomarkers have been identified thus far
using MS, which has since been expanded to include IMS [11,16],
a technique that enables analysis and visualization of the
distribution of individual biomolecules in any area of a tissue
section [17]. Thus, this approach is potentially of great signifi-
cance.
One IMS sequence creates a number of spectrums. To obtain
valid information from these spectrums, we performed the
addition of an adduct ion. In biological tissue, lipids tend to be
positively charged by a proton, sodium, and a potassium ion,
which indicates that the distribution of the positive ion influences
the distribution of lipids; different values tend to be obtained in the
IMS analysis results. In this study, we added potassium salt to the
matrix based on reports of Sugiura and co-workers who selectively
analyzed PC with different fatty acid compositions by the addition
of potassium salt to the matrix solution [18]. When added to the
Figure 3. Visualization of molecular distribution in case 1. We visualized ion images corresponding to the results shown in Table 1. In all
images, the cancer tissue is on the left and normal tissue is on the right. The distribution of the intensity for each m/z value was not constant in the
cancer and normal thyroid tissue.
doi:10.1371/journal.pone.0048873.g003
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matrix, the potassium salt solution caused a merging of various ion
adducts (adducts with proton, sodium, and potassium) into one
single potassiated species. This approach enabled us to reduce a
number of peaks and made it easier to identify molecules of
interest.
In the previous report, we demonstrated the feasibility of IMS as
a tool for the analysis of pathological specimens [19]. We showed
that IMS can be used to profile biological molecules, including
subtypes of PLs. We focused on the distribution of PLs in thyroid
papillary cancer. PLs are present as a constituent of the cell
membrane and are also expressed in cancer tissue. The intensities
of most m/z values in cancerous regions are higher than those in
normal regions; however, the intensity of some values (m/z 772.5,
782.5 and 848.5) in cancer regions was lower than that in normal
regions of tissue (see Figure 2 and Table 1). In general, malignant
cellular proliferation was stimulated due to cell growth factors,
which induce an increase in cell density and components of cancer
cells such as PLs. PLs are comprised of numerous combinations of
lipids that are based on their length, degree of acyl chain satiation,
and the polar head group. Figure 2 suggests that these differences
in intensity may arise from the distribution of the thyroid cancer-
specific fatty acids that are attached to PLs.
In breast cancer, PLs, especially PCs, in cancer tissues were
reported to have a relatively high level of linoleic acid (18:2) and
low levels of stearic acid (18:0) [20] and oleic acid (18:1) [21],
when compared with normal breast tissue. Luisa et al. identified
the pattern in the PL pattern and class differences in breast cancer
cells [22]. In their report, cancer cells showed a high relative
abundance of PC (16:0/18:1) and PC (18:1/18:1) corresponding
to [MH]+ at m/z 760 and 786. For SM, SM (18:1/16:0)
corresponding to [MH]+ at m/z 703 was detected mainly in
cancer cells.
Another previous report showed that the mRNA of 1-
acylglycerol-3-phosphate-O-acyltransferase (AGPAT) 11 that effi-
ciently uses LPA (18:1) as an acyl acceptor and fatty acid 18:1 as
an acyl donor is significantly up-regulated in human breast and
cervical cancer [23]. Our results show that the m/z 798.5 peaks
contain fatty acid C18:1, and they are expressed strongly in
thyroid cancer regions. While a previous study revealed the
selection of specific fatty acid-binding PLs, we provide more
information on the relative changes of PLs in thyroid papillary
cancer.
In Figure 4, distribution of the intensity in m/z 741.5
corresponded to [SM (d18:0/16:1)+K]+ and is different from the
intensity distribution in the others except for case 1 and 5. HE-
staining results showed that the area in which m/z 741.5 intensity
is expressed strongly mainly consisted of stromal and cancer
regions. We reported that the intensity of expressed SM was
higher in cancer and stromal regions than in normal regions in a
study of colon cancer liver metastasis [19]. Our result was
consistent with this report.
Stearoyl-CoA desaturase 1 (Scd1) is the rate limiting enzyme in
the cellular synthesis of monounsaturated fatty acids, including
C18:1, from saturated fatty acids. Falvella et al. reported that Scd1
gene overexpression is associated with hepatocarcinogenesis in
mice [24]. Scaglia et al. reported that inhibition of Scd1 expression
in human lung cancer cells impairs tumorigenesis, whereas the rate
of apoptosis was elevated [25]. These reports indicate that Scd1
causes an increase in C18:1 in cancer tissue.
The type of fatty acid influences cell shape and cell membrane
fluidity [9]. The alterations of cancer cell membrane fluidity may
influence the biological behavior of cancer such as invasion/
metastasis. IMS is the only tool that allows for the visualization of
the binding of fatty acids to PLs on tissue sections. Recently, an
increasing number of reports has focused on the relationship
between pathological insults and PLs, including PCs [26], i.e., the
remodeling pathway of PLs [27]. It is expected that IMS analysis
will help to achieve a better understanding of the relationship
between fatty acids and cancer mechanisms.
Using IMS, we directly profiled PC and SM expression from
tissue samples. This explorative profiling of PL on the basis of IMS
analysis provided results that emphasize the potential of IMS for
pathological diagnoses. The potential application of IMS analysis
in the clinical workflow has been suggested in a previous report
[28]. Compared to conventional methods such as MS and
immunohistochemistry, IMS has certain advantages as a clinical
Table 2. Overview of the m/z values that had higher
expression levels in cancer regions of all cases.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
798.5* 798.5* 701.8 798.5* 798.5* 798.7* 798.4*
796.5* 741.5* 676.8 796.5* 741.5* 796.7* 824.4
618.1 796.5* 675.9 820.5 772.5 824.7 796.4*
529.6 824.5 700.8 822.5 796.5* 822.6 822.4
580.2 772.5 704.8 772.5 824.5 826.7 820.4
504.2 760.6 798.5* 741.5* 599.0 820.6 760.5
741.5* 826.6 796.4* 826.5 820.5 748.3 826.5
664.2 822.5 820.4 782.5 782.5 760.8 782.4
584.1 782.5 824.5 822.5 618.2 848.4
622.0 820.5 822.5 583.1 642.2 772.5
527.2 748.2 848.5 826.5 772.6 786.5
542.3 758.5 509.3 848.5 848.7 741.5*
615.0 848.5 741.6* 725.6 782.7 758.4
546.2 786.6 772.4 850.5 741.8* 846.4
704.1 725.6 825.5 756.5 580.3 784.5
659.8 784.6 846.4 748.2 758.7 850.5
666.2 691.3 850.5 844.4 774.3 748.1
508.3 851.6 849.5 846.4 786.8 810.5
561.0 846.4 844.4 760.6 784.7 844.3
620.2 810.5 782.5 780.5 746.4 788.5
589.1 849.5 893.6 808.5 644.1 734.5
770.5 851.6 810.6 810.7 806.4
734.6 828.5 504.3 703.5
850.6 786.6 844.5 770.1
844.4 758.6 828.6 534.5
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application. Sample purification and extraction is necessary prior
to MS analysis. In addition, the performance of an antibody-based
assay in immunohistochemistry is always degraded to easily
observed changes in intensity or localization. On the other hand,
IMS analysis requires only a simple pretreatment, i.e., matrix
deposition and fixing the IMS condition settings. This means that
time is not lost between sample collection and analysis. It is
predicted that IMS will be readily introduced into the pathological
examination setting.
Recent studies have provided evidence of the clinical benefits of
IMS analysis, namely, that its profiles discriminate between other
diseases and prostate cancer [29] and the HER2 status of breast
cancer [30]. In these reports, IMS enabled the classification of
morphological and diagnostic features. A recently developed
Figure 4. Visualization of molecular distribution of m/z values that were expressed to higher levels in cancer tissue from all cases.
The ROI of each case is defined by a dashed line in HE-staining images. The intensity of all values in the cancer region was higher than in normal
regions. The distribution of intensity in m/z 741.5 was different from the distribution of intensity in the other m/z values.
doi:10.1371/journal.pone.0048873.g004
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variant of IMS analysis, referred to as ‘‘targeted imaging mass
spectrometry’’ (TIMS), was described by Thiery and colleagues
[31]. Such targeted analysis enabled the visualization of molecules
of interest directly from the tissue section by the use of laser
reactive photocleavable molecular tags attached to antibodies.
This approach provides quantification by estimating the signal
intensity, and an excellent signal-to-noise ratio in the resulting
spectrums. It is important to note that this diagnosis was made on
a single sample section; few cancer biopsies were available, and
more would be needed to quantitate a biomarker by IHC. In the
future, IMS analysis will provide new biomarkers and in turn, new
pathological categories, and could therefore become a critical
diagnostic tool in the clinical setting.
Materials and Methods
Ethics statement
Sample collection and archiving of patient data was performed
using written informed consent, and was approved by the ethical
committee of Kyoto University. This study was performed in
accordance with the Kyoto University guidelines for pathological
specimen handling.
1. Sample preparation
Seven Japanese patients who underwent routine thyroidectomy
at Kyoto University Hospital were involved in the present study.
Six women and one man were included and the average patient
age was 52 years. There was no recurrence in all cases. Samples
were obtained from a thyroid cancer section and adjacent normal
tissue immediately after tumor resection. The pathological
diagnosis was papillary thyroid carcinoma. The obtained tissue
was frozen in liquid nitrogen immediately to minimize degradation
and was kept at 280uC. The tissue sections were sliced to a
thickness of 10 mm using a Cryostat (CM 1950; Leica, Wetzler,
Germany). One section was mounted onto an indium-tin-oxide-
coated (ITO) glass slide for IMS analysis. Another section adjacent
to that used for IMS was mounted onto a glass slide (MAS coat;
Matsunami, Osaka, Japan) for HE staining to identify cancer and
normal thyroid regions.
2. Matrix deposition
The matrix solution was prepared by dissolving 50 mg 2, 5-
dihydroxybenzoic acid (DHB; Bruker Daltonics, Leipzig, Ger-
many) in 1 mL 70% methanol and 10 mM potassium acetate.
DHB is a widely used matrix for low molecular weight molecules.
Figure 5. Identified molecules. (A) MS/MS data of m/z 798.5. The structure of one peak was analyzed. The product ion spectrum of m/z 798.5 as a
precursor ion was obtained by MS/MS of thyroid papillary cancer region. This biomolecule was identified by neutral loss as [PC (16:0/18:1)+K]+. In the
same manner, in (B) m/z 796.5 was identified as [PC (16:0/18:2)+K]+. (C) m/z 741.5 was identified as [SM (d18:0/16:1)+K]+.
doi:10.1371/journal.pone.0048873.g005
The Expression of Phospholipid in Thyroid Cancer
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e48873
The addition of potassium salt to the matrix solution caused a
merging of various ion adducts into one single potassiated species.
This approach enabled us to reduce the number of peaks and
simplified the identification of molecules of interest. A thin matrix
layer was applied to the surface of the tissue sections using a 0.2-
mm nozzle airbrush (Procon Boy FWA Platinum; Mr. Hobby,
Tokyo, Japan) maintained at 15 cm from the tissue surface. The
total amount of matrix solution on each slide was 1 mL. The
spraying technique enabled full matrix coverage over the entire
tissue surface and facilitated the co-crystallization of the matrix
and bio-molecules.
3. Imaging mass spectrometry analysis
The tissue sections were analyzed using a matrix-assisted laser
desorption/ionization-time-of-flight/time-of-flight (MALDI-
TOF/TOF)-type instrument, Ultraflex II TOF/TOF (Bruker
Daltonics), which was equipped with a 355-nm Nd: YAG laser at
200 Hz repetition. Data were acquired in the positive-ion mode
using an external calibration method with ions from DHB,
angiotensin II and bradykinin. Their decomposition products
covered from m/z 100 to 1200. Calibration proteins were
deposited on the surfaces of sample materials. Each raster scan
was automatically performed in the regions of cancer and normal
tissue. The interval between data points was 100-mm, and 100
laser beam shots were irradiated on each data point. The mass
spectrometry parameters were optimized manually to obtain the
highest sensitivity with m/z values in the range of 400–900. All
spectra were acquired automatically using flexImaging 2.1
software (Bruker Daltonics), and the file format was converted to
enable analysis with Biomap (http://www.maldi-msi.org) and
SIMtools software (in-house software; Shimadzu Corporation).
The ion image was visualized using Biomap software.
4. Comparison of signal intensities between cancer and
normal thyroid regions
IMS analysis results were integrated, and the ROI in cancer and
normal thyroid tissues were defined corresponding to HE results
using SIMtools software. The top 50 peaks excluding isotopic
peaks were picked from ROI that was defined as cancer and
normal thyroid region, and the statistical difference was deter-
mined by Welch t-test. Differences with p,0.01 were considered
significant.
5. Comparison of results for all cases
We performed IMS and statistical analysis on all cases, and
picked the m/z value that had significantly higher expression in
cancer regions and was common in all cases.
6. Molecular identification
The common m/z values in all cases were employed for MS/
MS analysis for molecule identification. MS/MS analysis was
performed on tissue sections in the positive-ion mode using
QSTAR Elite (Applied Biosystems/MDS Sciex, Foster City, CA,
USA), a hybrid quadrupole/TOF mass spectrometer equipped
with an orthogonal MALDI source and a pulsed Nd: YAG laser.
Metabolite MS Search was used to determine the molecular
species of PLs. The matrix solution was prepared in the same way
as for IMS analysis. The mass spectrometry parameters were
optimized manually to obtain the highest sensitivity with m/z
values in the range of 100–850.
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